semaglutide for alzheimer's ameliorates disease and restores oxytocin in APP/PS1 mice and human brain organoid models Ozempic linked to lower Alzheimer's

These antibody drugs have a relatively long half-life, allowing less frequent dosing compared to traditional peptide drugs

Origen de los GLP-1 Los frmacos GLP-1 se desarrollaron originalmente para tratar a personas con diabetes tipo 2 y su uso clnico comenz a mediados del ao 2000

References Richie JP Jr, et al

The average 7-12 year delay from symptom onset to diagnosis reflects systemic failures in medical education, clinical assessment, and healthcare system organization rather than inherent limitations of medical knowledge or technology

Their established safety profile in metabolic disorders makes them attractive alternatives, though concerns remain about long-term effects, cost, and accessibility